Paliperidone “Approvable” Puts Pressure On J&J Evergreening Strategy

While not unexpected, the regulatory delay means the company will have less time to transition patients to the Risperdal follow-on.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet